February 2025 saw a mix of all-new models, feature upgrades, and special editions with SUVs dominating the list.

Equities research analysts at StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) in a research report issued on Wednesday. The brokerage set a “sell” ...

Syros Pharmaceuticals said it plans to wind down its operations, according to a Securities and Exchange Commission filing. The Cambridge, Mass., company said it would proceed with a voluntary ...

India's sub-4 metre compact SUV segment is fiercely competitive, offering some formidable options like the Maruti Suzuki ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its ...

The entry-level HTK variant, which is one of the six variants that the Syros is offered in, has now started arriving at local ...

EST Syros Pharmaceuticals (SYRS) trading halted, news pendingDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

The Kia Syros is the latest addition to the lineup of cars in India and comes at a starting price of Rs 9 lakh (ex-showroom).

The 1930s-set, six-part drama series about a woman trying to break free from tradition adapts one of the great Greek novels ...

With a mere difference of Rs 10,000, should you choose the mid-spec variant of Syros or the Sonet? The Kia Syros was launched ...

India’s passenger vehicle market continued to show resilience in Feb 2025, with total sales of the top 10 best-selling models ...

Syros gets two engine options – a 1.0-litre, 3-cylinder, turbo-petrol which puts out 120hp of power and 172Nm torque. It ...